LRI Investments’s Denali Therapeutics DNLI Stock Holding History

LRI Investments’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$77	Buy	+3	New	+$62	﹤0.01%	1871

Other funds holding DNLI

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

EOJOAM

E. Ohman J:or Asset Management Stockholm, Sweden $4.3B AUM 29.55% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

PFC

Phocas Financial Corp Alameda, California $721M AUM 63.77% 1-Year Est. Return

KOCAA

Knights of Columbus Asset Advisors New Haven, Connecticut $2B AUM 42.86% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

LRI Investments's DNLI Position: Q2 2026 in Review

LRI Investments opened a new position in Denali Therapeutics (DNLI) in Q2 2026: 3 shares worth $77. The stake represents ﹤0.01% of the portfolio and ranks #1871 among its holdings.

60 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

LRI Investments held 3 shares of Denali Therapeutics worth $77 as of Q2 2026.
Denali Therapeutics was a new LRI Investments position in Q2 2026.
Denali Therapeutics made up ﹤0.01% of LRI Investments's portfolio in Q2 2026, its #1871 holding.
60 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on LRI Investments's 13F filing for Q2 2026, filed 14 Jul 2026.